Anova to Manage Study of DB107 Following Newly Awarded $11.8M CIRM Grant
United States Food and Drug Administration (FDA) Authorizes Phase 2 Study of DB107 In Promising Turn-Around of Targeted Treatment to Treat Newly Diagnosed High Grade Glioma